ArticleNucleic acids research2026
EWAS Open Platform 2026: a deeply integrated resource for epigenome-wide association studies.
Article in Nucleic acids research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- CpG Atlas: A centralized multi-layer database and AI interface for DNA methylation research.bioRxiv : the preprint server for biology · 2026Article
- Methadone Maintenance Treatment vs. Long-Term Abstinence Without Opioid Agonist: Epigenome-Wide Study of DNA Methylation.Epigenomes · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
Abstract
Epigenome-wide association studies (EWAS) has become an indispensable approach for elucidating the epigenetic basis of complex traits. EWAS Open Platform (https://ngdc.cncb.ac.cn/ewas/) includes three main components: EWAS Atlas (curated associations from publications), EWAS Data Hub (normalized DNA methylation array data), and EWAS Toolkit (one-stop analysis services). Here, we present a new release of EWAS Open Platform with the following significant updates and enhancements: (i) Expanded information: EWAS Atlas houses over 800 000 associations and incorporates an additional 17 000 curated causal relationships. EWAS Data Hub contains >180 000 batch-corrected samples, which incorporate data from newly added Illumina MethylationEPIC v2.0 BeadChip (935K) as well as trait-specific methylation profiles. EWAS Toolkit now provides an online batch correction tool and an interactive epigenetic causal network. (ii) Enhanced interoperability: data, knowledge, and toolkit are fully interconnected through a unified retrieval, offering integrated summaries and visualization capabilities. (iii) Artificial intelligence (AI)-based service: the platform is newly equipped with an AI-assisted question-answering service, allowing users to interactively explore EWAS-related questions and generate tailored insights. Taken together, EWAS Open Platform has undergone a significant upgrade across data resources, analytical tools, and service functionalities, offering more advanced support for unraveling complex molecular mechanisms from an epigenomic perspective.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.